Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a historical-control phase III study
Mercedes P Jacobson, Ladislav Pazdera, Perminder Bhatia, Todd Grinnell, Hailong Cheng, David Blum, study 046 team, Mercedes P Jacobson, Ladislav Pazdera, Perminder Bhatia, Todd Grinnell, Hailong Cheng, David Blum, study 046 team
Abstract
Background: Eslicarbazepine acetate (ESL, Aptiom®) is a once-daily (QD) anticonvulsant, approved as adjunctive treatment of partial-onset seizures (POS). It is extensively converted after oral administration to eslicarbazepine, and is believed to exert its effect through inhibition of voltage-gated sodium channels. The possible role of ESL as monotherapy to treat POS has not yet been established.
Methods: This study was an 18-week, multicenter, randomized double-blind trial of gradual conversion to ESL monotherapy in adults with POS not well controlled by 1-2 antiepileptic drugs (AEDs), using historical data as the control. The study comprised an 8-week baseline period, a 2-week titration period, a 6-week AED conversion period, a 10-week monotherapy period, and either a 1-week taper period or optional entry to an open-label extension study. The primary endpoint compared the Kaplan-Meier (KM)-estimated 112-day exit rate with a threshold value calculated from the historical controls.
Results: There were 172 randomized patients; 154 (90%) entered the AED conversion period and 121 (70%) completed the study. The KM-estimated exit rates [confidence interval (CI)] were 15.6% [8.1-28.7%] for ESL 1200 mg, and 12.8% [7.5-21.5%] for ESL 1600 mg. The upper limits of the 95% CI KM-estimates were below the pre-specified threshold for historical control of 65.3%, indicating that ESL was efficacious in reducing seizure-related exits, compared with historical control. During the 18-week double-blind treatment period, median reductions in standardized seizure frequency occurred with ESL 1200 mg (36.1%) and ESL 1600 mg (47.5%). The responder rates (a 50% or greater reduction in seizure frequency from baseline) during the 18-week double-blind period and the monotherapy period, respectively, were 35.2% and 38.9% for ESL 1200 mg, and 46.0% and 46.0% for ESL 1600 mg. The overall adverse event profile was consistent with the known safety profile of ESL.
Conclusions: These findings indicate that ESL monotherapy (1200 and 1600 mg QD) was efficacious and well tolerated in this study.
Trial registration: NCT01091662 ; EudraCT No. 2010-018684-42.
Figures
References
- Banerjee PN, Filippi D, Allen Hauser W. The descriptive epidemiology of epilepsy – a review. Epilepsy Res. 2009;85:31–45. doi: 10.1016/j.eplepsyres.2009.03.003.
- Duncan JS, Sander JW, Sisodiya SM, Walker MC. Adult epilepsy. Lancet. 2006;367:1087–100. doi: 10.1016/S0140-6736(06)68477-8.
- Perucca E. Designing clinical trials to assess antiepileptic drugs as monotherapy. CNS Drugs. 2008;22:917–38. doi: 10.2165/00023210-200822110-00003.
- Perucca E, Tomson T. The pharmacological treatment of epilepsy in adults. Lancet Neurol. 2011;10:446–56. doi: 10.1016/S1474-4422(11)70047-3.
- St. Louis EK, Rosenfeld WE, Bramley T. Antiepileptic drug monotherapy: the initial approach in epilepsy management. Curr Neuropharmacol. 2009;7:77–82. doi: 10.2174/157015909788848866.
- Perucca E, French J, Bialer M. Development of new antiepileptic drugs: challenges, incentives, and recent advances. Lancet Neurol. 2007;6:793–804. doi: 10.1016/S1474-4422(07)70215-6.
- Almeida L, Potgieter JH, Maia J, Potgieter MA, Mota F, Soares-da-Silva P. Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment. Eur J Clin Pharmacol. 2008;64:267–73. doi: 10.1007/s00228-007-0414-1.
- Brown ME, El-Mallakh RS. Role of eslicarbazepine in the treatment of epilepsy in adults with partial-onset seizures. Ther Clin Risk Manag. 2010;6:103–9.
- Hebeisen S, Brady K, Konrad D, Soares-da-Silva P. Inhibitory effects of eslicarbazepine acetate and its metabolites against neuronal voltage-gated sodium channels. Epilepsia. 2011;52(s6):257–8.
- Prescribing information . Aptiom® (eslicarbazepine acetate) Marlborough MA, USA: Sunovion Pharmaceuticals Inc; 2013.
- Nunes T, Rocha JF, Falcão A, Almeida L, Soares-da-Silva P. Steady-state plasma and cerebrospinal fluid pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine in healthy volunteers. Epilepsia. 2013;54:108–16. doi: 10.1111/j.1528-1167.2012.03595.x.
- Ben-Menachem E, Gabbai AA, Hufnagel A, Maia J, Almeida L, Soares-da-Silva P. Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy. Epilepsy Res. 2010;89:278–85. doi: 10.1016/j.eplepsyres.2010.01.014.
- Elger C, Halasz P, Maia J, Almeida L, Soares-da-Silva P. BIA-2093-301 Investigators Study Group: Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study. Epilepsia. 2009;50:454–63. doi: 10.1111/j.1528-1167.2008.01946.x.
- Sperling M, Harvey J, Biraben A, Galimberti C, Kowacs P, Hong SB, et al. Adjunctive eslicarbazepine acetate in patients with refractory partial-onset seizures: Efficacy results of a 12 week randomized placebo-controlled study. Abst. 3.210. Epilepsy Curr. 2014;14(s1):395.
- Abou-Khalil B, Rogin JB, Biraben A, Galimberti C, Kowacs P, Hong SB, et al. Eslicarbazepine acetate as adjunctive therapy in patients with refractory partial-onset seizures: Safety results of a 12-week randomized placebo-controlled study. Abst. 2.128. Epilepsy Curr. 2014;14(s1):210–1.
- Summary of product characteristics. Zebinix® (eslicarbazepine acetate). Portugal: BIAL–Portela & Ca S.A., S. Mamede do Coronado, Portugal; 2013.
- French JA, Wang S, Warnock B, Temkin N. Historical control monotherapy design in the treatment of epilepsy. Epilepsia. 2010;51:1936–43. doi: 10.1111/j.1528-1167.2010.02650.x.
- Baulac M, Brodie MJ, Patten A, Segieth J, Giorgi L. Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurol. 2012;11:579–88. doi: 10.1016/S1474-4422(12)70105-9.
- Kwan P, Brodie MJ, Kälviäinen R, Yurkewicz L, Weaver J, Knapp LE. Efficacy and safety of pregabalin versus lamotrigine in patients with newly diagnosed partial seizures: a phase 3, double-blind, randomised, parallel-group trial. Lancet Neurol. 2011;10:881–90. doi: 10.1016/S1474-4422(11)70154-5.
- Leber PD. Hazards of inference: the active control investigation. Epilepsia. 1989;30(s1):64–8. doi: 10.1111/j.1528-1157.1989.tb05816.x.
- Sperling M, Harvey J, Blum D, Grinnell T. Conversion to monotherapy with eslicarbazepine acetate in adults with partial-onset seizures - results of a North-American study. Abst. 3.293. Epilepsy Curr. 2014;14(s1):431–2.
- Commission on Classification and Terminology of the International League Against Epilepsy (ILAE) Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia. 1981;22:489–501. doi: 10.1111/j.1528-1157.1981.tb06159.x.
- Borghs S, de la Loge C, Cramer A. Defining minimally important change in QOLIE-31 scores: Estimates from three placebo-controlled lacosamide trials in patients with partial-onset seizures. Epilepsy Behav. 2012;23:230–4. doi: 10.1016/j.yebeh.2011.12.023.
- Duru G, Fantino B. The clinical relevance of changes in the Montgomery-Asberg depression rating scale using the minimum clinically important difference approach. Curr Med Res Opin. 2008;24:1329–35. doi: 10.1185/030079908X291958.
- French JA, Temkin NR, Shneker BF, Hammer AE, Caldwell PT, Messenheimer JA. Lamotrigine XR conversion to monotherapy: first study using a historical control group. Neurotherapeutics. 2012;9:176–84. doi: 10.1007/s13311-011-0088-3.
- Boggs JG, Nowack WJ, Drinkard CR. Analysis of the “honeymoon effect” in adult epilepsy patients. Epilepsia. 2000;41(Suppl. 7):222.
- Kutlu G, Gomceli YB, Erdal A, Inan LE. The honeymoon effect in adult patients with refractory partial-onset epilepsy under levetiracetam add-on treatment. Epilepsia. 2013;19:15–8. doi: 10.5505/epilepsi.2013.48568.
- Loscher W, Schmidt D. Experimental and clinical evidence of loss of effect (tolerance) during prolonged treatment with antiepileptic drugs. Epilepsia. 2006;47:1253–84. doi: 10.1111/j.1528-1167.2006.00607.x.
- Chung S, Ceja H, Gawłowicz J, Avakyan G, McShea C, Schiemann J, et al. Levetiracetam extended release conversion to monotherapy for the treatment of patients with partial-onset seizures: a double-blind, randomised, multicentre, historical control study. Epilepsy Res. 2012;101:92–102. doi: 10.1016/j.eplepsyres.2012.03.007.
- Wechsler RT, Li G, French J, O’Brien TJ, D’Cruz O, Williams P, Goodson R, Brock M, the ALEX-MT Study Group et al. Conversion to lacosamide monotherapy in the treatment of focal epilepsy: Results from a historical-controlled, multicenter, double-blind study. Epilepsia. 2014;55(7):1088–98. doi: 10.1111/epi.12681.
- French JA, Kwan P, Fakhoury T, Pitman V, DuBrava S, Knapp L, Yurkewicz L, et al. Pregabalin monotherapy in patients with partial-onset seizures. A historical-controlled trial. Neurology. 2014;82(7):590–7. doi: 10.1212/WNL.0000000000000119.
- WHO Collaborating Center for Drug Statistics Methodology. ATC/DDD Index []. Accessed March 19, 2014.
Source: PubMed